| SBUX |
Report |
U.S. comparable sales growth |
BEAT |
pred ~6.8% vs. cons 6.0% |
MEDIUM |
| SBUX |
Report |
Adjusted EPS |
BEAT |
pred ~$0.67 vs. cons $0.65 |
MEDIUM |
| SBUX |
Report |
Consolidated operating margin |
IN-LINE |
pred ~12.4% vs. cons 12.33% |
MEDIUM |
| SBUX |
Guide |
Adjusted EPS guidance |
UNCHANGED |
guide ~$2.40 midpoint vs. cons $2.40 (FY2026) |
MEDIUM |
| SBUX |
Guide |
Global comparable-sales growth guidance |
BETTER |
guide ~5.5% vs. cons 5.4% (FY2026) |
MEDIUM |
| SBUX |
Guide |
Consolidated operating-margin growth guidance |
LOWER |
guide ~+20 bps YoY vs. cons +30 bps YoY (FY2026) |
LOW |
| SBUX |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.7% |
— |
MEDIUM |
| SBUX |
Return |
5-day cumulative residual |
+0.8% (FADE) |
Day-5 residual ~+0.8% vs. day-1 ~+2.7%: transaction-led comps and a modest EPS beat support the initial reaction, but unchanged FY2026 EPS guidance and ~10 bps of margin-guide shortfall imply limited Q4/FY2027 estimate upside, causing revisions to lag the headline beat. |
MEDIUM |